Cargando…

The use of long-acting injectable antipsychotics in an acute psychiatric unit

INTRODUCTION: Long-acting injectable antipsychotic (LAI) are an important and arguably under-utilized therapeutic option, particularly where medication adherence is a priority (Pilon et al. Clin Ther 2017; 39 1972-1985). In recent years, meta-analytic reviews of depot medications concluded that this...

Descripción completa

Detalles Bibliográficos
Autores principales: Ortega-Hernández, G., Ramiro, N., Palma-Álvarez, F., Soto-Angona, Ó., Mantilla, M. F., Duque, J., Gonzalo, I., Collazos, F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10595825/
http://dx.doi.org/10.1192/j.eurpsy.2023.438
_version_ 1785124959998181376
author Ortega-Hernández, G.
Ramiro, N.
Palma-Álvarez, F.
Soto-Angona, Ó.
Mantilla, M. F.
Duque, J.
Gonzalo, I.
Collazos, F.
author_facet Ortega-Hernández, G.
Ramiro, N.
Palma-Álvarez, F.
Soto-Angona, Ó.
Mantilla, M. F.
Duque, J.
Gonzalo, I.
Collazos, F.
author_sort Ortega-Hernández, G.
collection PubMed
description INTRODUCTION: Long-acting injectable antipsychotic (LAI) are an important and arguably under-utilized therapeutic option, particularly where medication adherence is a priority (Pilon et al. Clin Ther 2017; 39 1972-1985). In recent years, meta-analytic reviews of depot medications concluded that this route of administration produced clinical advantages in terms of overall outcome, with lower probability of relapse, readmissions, shorter hospital admission time, mortality, and thus better long- term prognosis over other oral antipsychotics (Leucht et al. Schizophr Res 2011;127 83-92). Depot treatment is associated with lower overall medical expenditure (Taipal et al. Schizophr Bull 2018;17 1381- 1387). OBJECTIVES: To describe the evolution of people diagnosed with a psychotic disorder 6 months before and after the introduction of long-acting injectable antipsychotic (LAI) in the acute psychiatric unit of San Rafael Hospital (Spain) from January 1, 2018 to December 31, 2018. METHODS: Retrospective and prospective naturalistic study. Patients with a diagnosis of psychotic disorder who were admitted to the acute psychiatric unit in 2018 and who were introduced to LAI (paliperidone palmitate, aripiprazole, olanzapine pamoate or risperidone), are selected. Sociodemographic variables (sex, age, ethnicity, migratory status, marital status, occupation, cohabitation) and clinical variables (main and secondary diagnosis, comorbidity with drug use and history of poor adherence) are described. The number of emergency visits and hospital admissions before and after the introduction of LAI antipsychotic treatment is compared. RESULTS: The sample was composed of 99 subjects. The mean age was 42.46 years (SD 13.439) and 67.7% were men. The socio-demographic profile was: european caucasian ethnicity (73.7%), non- migrant status (69.7%), single (67.7%), inactive (43.4%) and residing in the home of relatives (50.5%). 53.5% have a diagnosis of schizophrenia, followed by schizoaffective disorder (24.2%). 45.5% are diagnosed with any drug use disorder, the most frequent being cannabis (30.3%). 76.8% have a history of discontinuing oral treatment. There was a statistically significant decrease (p<0.0001) in number of emergency visits and hospital admissions after the introduction of LAI antipsychotic. In the general linear multivariate before-after model, there were significant differences (p=0.002) in the number of admissions after long-term IM antipsychotic treatment. As for the comparison of the effects between the different LAIs, there are differences between them (p< 0.0001). Post-hoc analysis (Bonferroni) only showed differential significance for treatment with Paliperidone Palmitate (p<0.0001). CONCLUSIONS: The use of LAI antipsychotic can reduce the number of emergency room visits and hospital admissions, in line with literature. DISCLOSURE OF INTEREST: None Declared
format Online
Article
Text
id pubmed-10595825
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cambridge University Press
record_format MEDLINE/PubMed
spelling pubmed-105958252023-10-25 The use of long-acting injectable antipsychotics in an acute psychiatric unit Ortega-Hernández, G. Ramiro, N. Palma-Álvarez, F. Soto-Angona, Ó. Mantilla, M. F. Duque, J. Gonzalo, I. Collazos, F. Eur Psychiatry Abstract INTRODUCTION: Long-acting injectable antipsychotic (LAI) are an important and arguably under-utilized therapeutic option, particularly where medication adherence is a priority (Pilon et al. Clin Ther 2017; 39 1972-1985). In recent years, meta-analytic reviews of depot medications concluded that this route of administration produced clinical advantages in terms of overall outcome, with lower probability of relapse, readmissions, shorter hospital admission time, mortality, and thus better long- term prognosis over other oral antipsychotics (Leucht et al. Schizophr Res 2011;127 83-92). Depot treatment is associated with lower overall medical expenditure (Taipal et al. Schizophr Bull 2018;17 1381- 1387). OBJECTIVES: To describe the evolution of people diagnosed with a psychotic disorder 6 months before and after the introduction of long-acting injectable antipsychotic (LAI) in the acute psychiatric unit of San Rafael Hospital (Spain) from January 1, 2018 to December 31, 2018. METHODS: Retrospective and prospective naturalistic study. Patients with a diagnosis of psychotic disorder who were admitted to the acute psychiatric unit in 2018 and who were introduced to LAI (paliperidone palmitate, aripiprazole, olanzapine pamoate or risperidone), are selected. Sociodemographic variables (sex, age, ethnicity, migratory status, marital status, occupation, cohabitation) and clinical variables (main and secondary diagnosis, comorbidity with drug use and history of poor adherence) are described. The number of emergency visits and hospital admissions before and after the introduction of LAI antipsychotic treatment is compared. RESULTS: The sample was composed of 99 subjects. The mean age was 42.46 years (SD 13.439) and 67.7% were men. The socio-demographic profile was: european caucasian ethnicity (73.7%), non- migrant status (69.7%), single (67.7%), inactive (43.4%) and residing in the home of relatives (50.5%). 53.5% have a diagnosis of schizophrenia, followed by schizoaffective disorder (24.2%). 45.5% are diagnosed with any drug use disorder, the most frequent being cannabis (30.3%). 76.8% have a history of discontinuing oral treatment. There was a statistically significant decrease (p<0.0001) in number of emergency visits and hospital admissions after the introduction of LAI antipsychotic. In the general linear multivariate before-after model, there were significant differences (p=0.002) in the number of admissions after long-term IM antipsychotic treatment. As for the comparison of the effects between the different LAIs, there are differences between them (p< 0.0001). Post-hoc analysis (Bonferroni) only showed differential significance for treatment with Paliperidone Palmitate (p<0.0001). CONCLUSIONS: The use of LAI antipsychotic can reduce the number of emergency room visits and hospital admissions, in line with literature. DISCLOSURE OF INTEREST: None Declared Cambridge University Press 2023-07-19 /pmc/articles/PMC10595825/ http://dx.doi.org/10.1192/j.eurpsy.2023.438 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstract
Ortega-Hernández, G.
Ramiro, N.
Palma-Álvarez, F.
Soto-Angona, Ó.
Mantilla, M. F.
Duque, J.
Gonzalo, I.
Collazos, F.
The use of long-acting injectable antipsychotics in an acute psychiatric unit
title The use of long-acting injectable antipsychotics in an acute psychiatric unit
title_full The use of long-acting injectable antipsychotics in an acute psychiatric unit
title_fullStr The use of long-acting injectable antipsychotics in an acute psychiatric unit
title_full_unstemmed The use of long-acting injectable antipsychotics in an acute psychiatric unit
title_short The use of long-acting injectable antipsychotics in an acute psychiatric unit
title_sort use of long-acting injectable antipsychotics in an acute psychiatric unit
topic Abstract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10595825/
http://dx.doi.org/10.1192/j.eurpsy.2023.438
work_keys_str_mv AT ortegahernandezg theuseoflongactinginjectableantipsychoticsinanacutepsychiatricunit
AT ramiron theuseoflongactinginjectableantipsychoticsinanacutepsychiatricunit
AT palmaalvarezf theuseoflongactinginjectableantipsychoticsinanacutepsychiatricunit
AT sotoangonao theuseoflongactinginjectableantipsychoticsinanacutepsychiatricunit
AT mantillamf theuseoflongactinginjectableantipsychoticsinanacutepsychiatricunit
AT duquej theuseoflongactinginjectableantipsychoticsinanacutepsychiatricunit
AT gonzaloi theuseoflongactinginjectableantipsychoticsinanacutepsychiatricunit
AT collazosf theuseoflongactinginjectableantipsychoticsinanacutepsychiatricunit
AT ortegahernandezg useoflongactinginjectableantipsychoticsinanacutepsychiatricunit
AT ramiron useoflongactinginjectableantipsychoticsinanacutepsychiatricunit
AT palmaalvarezf useoflongactinginjectableantipsychoticsinanacutepsychiatricunit
AT sotoangonao useoflongactinginjectableantipsychoticsinanacutepsychiatricunit
AT mantillamf useoflongactinginjectableantipsychoticsinanacutepsychiatricunit
AT duquej useoflongactinginjectableantipsychoticsinanacutepsychiatricunit
AT gonzaloi useoflongactinginjectableantipsychoticsinanacutepsychiatricunit
AT collazosf useoflongactinginjectableantipsychoticsinanacutepsychiatricunit